Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Stretch Mark Remedies

China Sky One Medical, Inc. Obtains SFDA Approval For Diclofenac Sodium Eye Drops
China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (Nasdaq: CSKI), a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People"s Republic of China ("PRC"), announced that it obtained approval from the State Food and Drug Administration (SFDA) in China for the production of Diclofenac Sodium eye drops. The document number for the drug is 2009S02063.
generic viagra online
ADHD Genes Found; Known To Play Roles In Neurodevelopment
Pediatric researchers have identified hundreds of gene variations that occur more frequently in children with attention-deficit hyperactivity disorder (ADHD) than in children without ADHD. Many of those genes were already known to be important for learning, behavior, brain function and neurodevelopment, but had not been previously associated with ADHD.
News of the day
Antibiotic Resistant Bacteria Found In Fertilizer
Vancomycin resistant enterococci (VRE) have been found in sewage sludge, a by-product of waste-water treatment frequently used as a fertilizer. Researchers writing in the open access journal Acta Veterinaria Scandinavica point out the danger of antibiotic resistance genes passing into the human food chain.
Public Health

GE Healthcare's Application For DaTSCAN™ (Ioflupane I123 Injection) Accepted By The FDA For Priority Review

GE Healthcare announced that the Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for DaTSCAN (Ioflupane I123 Injection) for priority review. DaTSCAN is a radiopharmaceutical agent containing Ioflupane (Âð²ÂöI) in development for a proposed indication of the detection of loss of functional nigrostraiatal dopaminergic neurons by single photon emission computed tomography (SPECT) imaging in patients presenting with symptoms or signs suggestive of dopaminergic neurodegeneration. A priority review designation is intended for drugs that offer major advances in treatment, or provide treatment where no adequate therapy exists. The FDA"s goal is to review and act on 90 percent of NDAs designated as priority review within six months of receipt. "We are very pleased that the FDA has accepted our NDA for DaTSCAN," said Don Black, MD, head of R&D for GE Healthcare Medical Diagnostics. "Acceptance of the NDA filing for priority review is an important milestone for GE Healthcare, and we will continue to work with the FDA with the objective of making DaTSCAN available in the United States." DaTSCAN has been available in Europe since 2000. In Europe, DaTSCAN is indicated for detecting loss of functional dopaminergic neuron terminals in the striatum in patients with clinically uncertain Parkinsonian Syndromes in order to help differentiate Essential Tremor from Parkinsonian Syndromes related to idiopathic Parkinson"s Disease (PD), Multiple System Atrophy (MSA), Progressive Supranuclear Palsy (PSP). DaTSCAN is unable to discriminate between PD, MSA and PSP. In Europe, it is also indicated to help differentiate probable dementia with Lewy bodies (DLB) from Alzheimer"s disease. DaTSCAN is unable to discriminate between DLB and Parkinson"s disease dementia. GE Healthcare


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009